Hypoalphalipoproteinemias: Clinical Trials

80 trials for Hypoalphalipoproteinemias, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

69 completed, 4 unknown, 3 recruiting, 3 terminated. 50 Phase 1, 12 Not applicable, 5 Phase 3, 3 Phase 4, 2 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 150Completed 47, Recruiting 1, Terminated 1, Withdrawn 1
Not applicable12Completed 7, Unknown 3, Recruiting 1, Terminated 1
Phase 35Completed 4, Terminated 1
Phase 43Completed 3
Early Phase 12Completed 1, Unknown 1
Phase 21Completed 1

Follow Hypoalphalipoproteinemias: new trials by email Literature Review of Hypoalphalipoproteinemias trials Research Report on Hypoalphalipoproteinemias

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Single and Multiple Dose Study to Evaluate Safety and Pharmacokinetics of BMS-986533 in Healthy Participants and Assessments of Food and pH Effects on Relative Bioavailability, and Drug-Drug Interaction Potential in Healthy Participants
BMS-986533, Famotidine, Placebo - Healthy Volunteers
Phase 1RecruitingBristol-Myers Squibb1362026-07-132026-07-24
The Food Effect on Pharmacokinetics of Fixed Dose Combination of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers
Fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg - Healthy, Fasting
Phase 1CompletedLG Chem282026-06-112026-09-10
A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants.
balcinrenone/ dapagliflozin, quinidine - Healthy Participants
Phase 1CompletedAstraZeneca142025-05-202025-08-12
Exploring Physical Exercise for the Regulation and Control of Metabolic Disorders in College Students.
Physical exercise prescription: Continuous aerobic training (jogging, swimming, static cycling), Control group: Continuous aerobic physical exercise - Metabolic Disorders, Abdominal Obesity
Not applicableUnknownUniversidad de Colima482024-09-012024-08-15
Atlantic Lipid Lowering Treatment Optimization Program
Supportive care - Familial Hypercholesterolemia, Lipoprotein Types--Lp System Lp(A) Hyperlipoproteinemia
Not applicableRecruitingAtlantic Health System2502024-07-012025-08-03
Pharmacokinetics of AUX-001 40mg Once-daily in Healthy Subjects Under Fasting and Fed Conditions
AUX-001 40mg once-daily - Chronic Stable Angina
Early Phase 1UnknownAuxilius Pharma sp.z.o.o.162023-11-272024-02-12
A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants
Iberdomide - Healthy Volunteers
Phase 1CompletedBristol-Myers Squibb322023-05-182024-07-26
Development of the Leeds Food Preference Questionnaire in Spanish
Standardized meal - Fasting, Fed
Not applicableUnknownUniversidad de Granada502023-03-072023-05-01
The Effect of Tele-Nursing Based Motivational Interviewing in Individuals With Type 2 Diabetes:RCT
Tele-Nursing based Motivational Interviewing - Type2 Diabetes, Self Efficacy
Not applicableCompletedPamukkale University702023-02-012024-03-13
Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers
Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®) - Healthy Volunteers, Fasting
Early Phase 1CompletedTAHO Pharmaceuticals Ltd.122022-12-052023-08-18
LCAT (Lecithin Cholesterol Acyl Transferase) Natural History Study
Demographics, diagnosis type, genotype, lipid profile, renal function profile, treatment allocation, ophthalmology exam, country of residence. - LCAT Deficiency
RecruitingUniversity of Pennsylvania402022-08-122026-05-06
Bioequivalence Study of Rivaroxaban 2.5 mg Tablets Under Fasting and Fed Conditions
Rivaroxaban 2.5 mg Test Tablet, Rivaroxaban 2.5 mg Reference Tablet - Healthy Participants
Phase 1CompletedThe Affiliated Hospital of Qingdao University642022-03-162026-09-08
Decrease in Paraoxonase Enzyme Level and Myocardial İnfarction
paraoxanase enzyme level - Myocardial Infarction, High-Density Lipoid Deficiency
CompletedBezmialem Vakif University2002019-12-302022-05-31
Adiponectin, ICAM-1, VCAM-1 Levels and Metabolic Syndrome in Obese Adolescents
Nur Aisiyah Widjaja - Obesity, Abdominal Obesity
CompletedUniversitas Airlangga1252019-10-012023-01-13
Intermittent Fasting in Dyslipidemia
Fasting (diet restruction for specific period) - Intermittent Fasting, Dyslipidemias
Not applicableUnknownAga Khan University602019-02-202019-02-21
The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients
Rosuvastatin 20mg, surgical castration - Prostate Cancer Metastatic
Phase 4CompletedNational Cancer Institute, Egypt702019-01-152021-03-02
Habitual Diet and Avocado Trial
Intervention Daily Avocado - Intra-abdominal Fat, Metabolic Syndrome
Not applicableCompletedWake Forest University Health Sciences10082018-06-192023-03-22
Investigation of Fat Oxidation During Moderate Versus Vigorous Intensity Exercise
Exercise - Healthy, Sedentary Lifestyle
Not applicableCompletedLatvian Institute of Organic Synthesis122018-06-182019-03-06
Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients?
Cosyntropin - Adrenal Insufficiency, Cirrhosis
Phase 3CompletedUniversity of Virginia1002018-01-292021-12-09
The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions
Dapagliflozin/metformin XR 5/500mg, Dapagliflozin/metformin XR 5/500 mg, Dapagliflozin/metformin XR 10/1000mg - Healthy Subjects in Fasted and Fed State
Phase 1CompletedAstraZeneca2842017-09-262018-05-30

Showing 20 of 80. Sign in to see all of them.

Narrower conditions

Lecithin Cholesterol Acyltransferase Deficiency (62)  ·  Fasting (17)  ·  Tangier Disease (5)  ·  Cardiovascular Diseases (3)  ·  Dyslipidemias (3)  ·  Hyperglycemia (3)  ·  Hypertension (3)  ·  Hypertriglyceridemia (3)  ·  Metabolic Syndrome (3)  ·  Atherosclerosis (2)  ·  Coronary Artery Disease (2)  ·  Hypercholesterolemia (2)  ·  Hyperlipoproteinemia Type II (2)  ·  Kidney Diseases (2)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (80)  ·  Lipid Metabolism Disorders (80)  ·  Metabolism, Inborn Errors (80)  ·  Nutritional and Metabolic Diseases (80)  ·  Genetic Diseases, Inborn (79)  ·  Hypolipoproteinemias (79)  ·  Lipid Metabolism, Inborn Errors (79)  ·  Metabolic Diseases (79)  ·  Dyslipidemias (77)  ·  Behavior (20)  ·  Feeding Behavior (17)  ·  Vascular Diseases (8)  ·  Cardiovascular Diseases (7)  ·  Pathological Conditions, Signs and Symptoms (7)

Interventions

Diet Therapy (3)  ·  Lisinopril (3)  ·  Metformin (3)  ·  dapagliflozin (3)  ·  Acetaminophen (2)  ·  Doxycycline (2)  ·  Etodolac (2)  ·  Morphine (2)  ·  Niacin (2)  ·  Olanzapine (2)  ·  Ondansetron (2)  ·  Rosuvastatin Calcium (2)  ·  Tablets (2)  ·  Tramadol (2)  ·  Ultracet (2)

Sponsors

IPCA Laboratories Ltd. (12)  ·  Par Pharmaceutical, Inc. (11)  ·  Dr. Reddy's Laboratories Limited (7)  ·  Pfizer (4)  ·  Isfahan University of Medical Sciences (3)  ·  National Heart, Lung, and Blood Institute (NHLBI) (3)  ·  Actavis Inc. (2)  ·  AstraZeneca (2)  ·  Bristol-Myers Squibb (2)  ·  Geropharm (2)  ·  University of Pennsylvania (2)  ·  Aga Khan University (1)  ·  Atlantic Health System (1)  ·  Auxilius Pharma sp.z.o.o. (1)  ·  Bezmialem Vakif University (1)

Countries

United States (21)  ·  India (15)  ·  Canada (8)  ·  Belgium (3)  ·  United Kingdom (3)  ·  Brazil (2)  ·  Indonesia (2)  ·  Iran (2)  ·  Mexico (2)  ·  Russia (2)  ·  Turkey (Türkiye) (2)  ·  China (1)  ·  Egypt (1)  ·  France (1)  ·  Israel (1)

Top investigators

Dr. Hardik Dave, M.B.B.S. (2)  ·  Dr. Rupesh Vala, M.B.B.S. (2)  ·  Dr. Suhas Khandave, M.D. (2)  ·  Dr. Tarang Shah, M.D. (2)  ·  Eric Masson, Pharm.D. (2)  ·  Leila Azadbakht, PhD (2)  ·  Marina Cuchel, MD, PhD (2)  ·  Robert D Shamburek, M.D. (2)  ·  Alan S. Marion, MD, PhD (1)  ·  Alpeshkumar Patel, MD (1)  ·  Andrei C Sposito, PhD (1)  ·  Andy Darma, Paediatrician (1)  ·  Anthony R Godfrey, Pharm.D. (1)

Results publications

PMID 12485966, PMID 16818923, PMID 17384344, PMID 18201934, PMID 22775199, PMID 23713767, PMID 23986778, PMID 24279738, PMID 24768191, PMID 25527677, PMID 25559009, PMID 26179237, PMID 26330422, PMID 26499033, PMID 26628614, PMID 26661397, PMID 27050191, PMID 27548405, PMID 27807041, PMID 28204912, PMID 29080546, PMID 30997650, PMID 32865503, PMID 33598473, PMID 34763335, PMID 34886337, PMID 34969419, PMID 35061234, PMID 35068165, PMID 35861827, PMID 35871953, PMID 36480560, PMID 38375072, PMID 38726886, PMID 39128497, PMID 39641169, PMID 39886351, PMID 39968784, PMID 39982630, PMID 41823253, PMID 42087898, PMID 9018491

NIH funding

2016 (1), 2023 (1), R01HL033973 (1), R56HL118343 (1)